The recent insider selling of Hilltop Holdings shares, without any insider buying in the past year, raises caution despite the company's profitability and growth. The high level of insider ownership suggests that management's incentives are well aligned with other shareholders.
High insider ownership usually implies management's interests align with shareholders. However, recent insider selling at Hilltop Holdings is worrying. The large ownership stake by insiders might still provide reassurance to shareholders.
Despite past year's losses, long-term investors gained 9% annually over five years. Steady market sentiment as share price largely tracks EPS growth. Current sell-off could signal an investment opportunity.
Gainers: •$イノビズ テクノロジズ(INVZ.US)$+18.7% (selected by "large automotive group manufacturer" to become its direct LiDAR supplier across multiple brands) •$ヒルトップ ホールディングス(HTH.US)$+15.7% (commenced a modified "Dutch auction" tender offer to purchase for cash up to $400 mln of its common stock at a price per share not less than $28,00 and not greater than $32.00 less any applicable withholding taxes and without interest usin...
18
3
2
報告
Dino 64 :
Nio is a pre market mover alright.....DOWN.
ヒルトップ ホールディングスに関するコメント
• $イノビズ テクノロジズ(INVZ.US)$ +18.7% (selected by "large automotive group manufacturer" to become its direct LiDAR supplier across multiple brands)
• $ヒルトップ ホールディングス(HTH.US)$ +15.7% (commenced a modified "Dutch auction" tender offer to purchase for cash up to $400 mln of its common stock at a price per share not less than $28,00 and not greater than $32.00 less any applicable withholding taxes and without interest usin...
• $A10ネットワークス(ATEN.US)$ +10.6% (to join S&P SmallCap 600)
• $SVB Financial(SIVB.US)$ +8.9% (earnings report)
• $レバンス セラピューティクス(RVNC.US)$ +8.9% (FDA accepts BLA resubmission for DaxibotulinumtoxinA for Injection)
• $UFPインダストリーズ(UFPI.US)$ +5.9% (also increases dividend)
• $JD.COM(京東商城)(JD.US)$ +3.8% (weighing payment of special cash dividend)
• $エスタブリッシュメント ラボズ ホールディングス(ESTA.US)$ +3.4% (Presentation of 2-Year Results from Motiva US...
まだコメントはありません